ISA Pharmaceuticals BV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ISA Pharmaceuticals BV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10510
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オランダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ISA Pharmaceuticals BV (ISA Pharmaceuticals) is a developer of synthetic therapeutic vaccines for the treatment of cancer and persistent viral infections. The company’s pipeline products include ISA101, an immunotherapeutic vaccine for cervical cancer; MyISA, a personalized immunotherapy based on neoantigens to eradicate cancer; ISA203, preferentially expressed antigen in melanoma for treating different types of cancers; and ISA204 for the treatment of hepatitis B. It also develops synthetic long peptides technology used in the applications of viral and non-viral targets and provides multiple products for persistent virus infections. The company also provides amplivant technology, which is based on a proprietary and synthetic toll-like receptor agonist and is used in new generation immunotherapeutic for treating various diseases. ISA Pharmaceuticals is headquartered in Leiden, the Netherlands.

ISA Pharmaceuticals BV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ISA Pharma Raises US$10 Million In Venture Financing 10
Partnerships 11
Regeneron Pharma and ISA Pharma Enter into Partnership 11
ISA Therapeutics Enters into R&D Agreement with Shin Nippon Biomedical Labs 12
Licensing Agreements 13
Scancell Enters into Licensing Agreement with ISA Pharma 13
ISA Pharmaceuticals BV – Key Competitors 14
ISA Pharmaceuticals BV – Key Employees 15
ISA Pharmaceuticals BV – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 17
Corporate Communications 17
May 23, 2018: ISA Pharmaceuticals Promotes Gerben Moolhuizen to Chief Executive Officer 17
Product News 18
05/23/2017: Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017 18
04/30/2018: ISA Pharmaceuticals Appoints Leon Hooftman as Chief Medical Officer 19
02/16/2017: Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC 20
Clinical Trials 21
Apr 26, 2018: ISA Pharmaceuticals’ ISA101 Studied in Phase II Oropharyngeal Cancer Combination Trial at MD Anderson Cancer Center 21
Sep 11, 2017: Combined Therapy with Nivolumab and ISA 101 Vaccine Results in Promising Efficacy in HPV-positive Oropharyngeal Cancer 22
Sep 04, 2017: Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Key Facts 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISA Pharmaceuticals BV, Deals By Therapy Area, 2012 to YTD 2018 8
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ISA Pharma Raises US$10 Million In Venture Financing 10
Regeneron Pharma and ISA Pharma Enter into Partnership 11
ISA Therapeutics Enters into R&D Agreement with Shin Nippon Biomedical Labs 12
Scancell Enters into Licensing Agreement with ISA Pharma 13
ISA Pharmaceuticals BV, Key Competitors 14
ISA Pharmaceuticals BV, Key Employees 15
ISA Pharmaceuticals BV, Subsidiaries 16

List of Figures
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISA Pharmaceuticals BV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ISA Pharmaceuticals BV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Engie SA (ENGI):企業の財務・戦略的SWOT分析
    Engie SA (ENGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • The Menarini Group:企業のM&A・事業提携・投資動向
    The Menarini Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Menarini Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Aernnova Aerospace, S.A.:企業の戦略・SWOT・財務情報
    Aernnova Aerospace, S.A. - Strategy, SWOT and Corporate Finance Report Summary Aernnova Aerospace, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Evergreen Fibreboard Berhad:企業の戦略・SWOT・財務情報
    Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report Summary Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Assicurazioni Generali SpA:企業のM&A・事業提携・投資動向
    Assicurazioni Generali SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Assicurazioni Generali SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • PT PLN (Persero):企業の発電所・SWOT分析2018
    PT PLN (Persero) - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Grand Gulf Energy Ltd (GGE):企業の財務・戦略的SWOT分析
    Summary Grand Gulf Energy Ltd (GGE), formerly Alto Energy International Ltd, is an oil and gas exploration and production company. It acquires, explores and develops conventional oil and gas assets in the US oil and gas basins. In addition, GGE also holds interests in Napoleonville Salt Dome project …
  • Xellia Pharmaceuticals ApS-製薬・医療分野:企業M&A・提携分析
    Summary Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products …
  • EnCana Corp (ECA):石油・ガス:M&Aディール及び事業提携情報
    Summary EnCana Corp (EnCana) is an oil and gas producer. The company explores, develops, produces and markets natural gas, oil and natural gas liquids (NGLs). Its major resource plays include Montney, Duvernay, Wheatland Oil play, Deep Panuke, Horn River and other emerging plays in Canada. In the US …
  • QinetiQ Group plc:企業のM&A・事業提携・投資動向
    QinetiQ Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's QinetiQ Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Fauji Fertilizer Bin Qasim Limited (FFBL)-エネルギー分野:企業M&A・提携分析
    Summary Fauji Fertilizer Bin Qasim Limited (FFBL) is a chemical manufacturing company that manufactures, supplies and markets di ammonium phosphate (DAP) and granular urea. In addition, the company undertakes production and marketing of ammonia and other nitrogenous fertilizers for agricultural appl …
  • Wolters Kluwer nv:企業の戦略・SWOT・財務情報
    Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report Summary Wolters Kluwer nv - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Franz Haniel & Cie. GmbH:企業の戦略的SWOT分析
    Franz Haniel & Cie. GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Sumitomo Osaka Cement Co Ltd:企業の戦略・SWOT・財務情報
    Sumitomo Osaka Cement Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Osaka Cement Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Gordon Food Service Inc:企業の戦略的SWOT分析
    Gordon Food Service Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Colabor Group Inc (GCL):企業の財務・戦略的SWOT分析
    Colabor Group Inc (GCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • H&R GmbH & Co KGaA (2HR):企業の財務・戦略的SWOT分析
    H&R GmbH & Co KGaA (2HR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Senex Energy Ltd (SXY):企業の財務・戦略的SWOT分析
    Summary Senex Energy Ltd (Senex) is an independent upstream oil and gas company. It mainly focuses on the east coast of Australia. The company acquires, explores, and develops oil and gas assets in the Surat and Cooper basins. It owns significant acreage in the basins with operatorship over all of i …
  • Barilla Holding S.p.A.:企業の戦略・SWOT・財務情報
    Barilla Holding S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Barilla Holding S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Gamma Solutions SL:電力:M&Aディール及び事業提携情報
    Summary Gamma Solutions SL (Gamma Solutions) is an engineering and consulting company that operates through energy, telecommunication, mobile and IT, and research and development divisions. The company offers products such as gamma start city monitoring system, photovoltaic rooftop monitoring system …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆